Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Dermatologic 2Classical hematology 2Sarcoma 1Lymphoid 1

Conditions

Anemia, Refractory, with Excess of Blasts 168Myelodysplastic Syndromes 160Leukemia 156Anemia 151Leukemia, Myeloid, Acute 144Neoplasms 124Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Leukemia, Myelomonocytic, Chronic 111Multiple Myeloma 90Myeloproliferative Disorders 89Leukemia, Lymphocytic, Chronic, B-Cell 87Lymphoma, Non-Hodgkin 76Hodgkin Disease 71Lymphoma 66Congenital Abnormalities 64Anemia, Refractory 64Venous Thromboembolism 63Thrombocytopenia 59Blast Crisis 57Leukemia, Myeloid, Chronic-Phase 56Leukemia, Myeloid, Accelerated Phase 52Lymphoma, Follicular 51Myelodysplastic-Myeloproliferative Diseases 48Anemia, Aplastic 46Primary Myelofibrosis 44Lymphoma, Mantle-Cell 44Neoplasms, Plasma Cell 43Lymphoma, Large B-Cell, Diffuse 41Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 41Burkitt Lymphoma 41

Interventions

Fentanyl 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Burns × Classical hematology × Clear all
NCT00236041 2014-05-09

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
38 enrolled
Classical hematology

Agnosia, Anemia, Sickle Cell, Burns, Neoplasms, Breakthrough Pain

NCT00236093 2014-05-09

Extension Study of ACTIQ Treatment for Children and Adolescents With Breakthrough Pain

Teva Branded Pharmaceutical Products R&D, Inc.

Phase 2 Completed
Classical hematology

Anemia, Sickle Cell, Burns, Neoplasms, Pain

Data powered by HemOnc (CC BY 4.0) Colophon âš¡